Biopharma Investing In Better Success Rates Via AI, Data And New Modalities
Biopharma executives and investors gathered in San Diego on Feb. 28 and March 1 to talk about finding and funding innovation with a focus on novel technology and artificial intelligence that can improve drug discovery and development success rates.
You may also be interested in...
Celgene will pursue "high-impact" indications using Vividion's proteomics technology, while Magenta will use Heidelberg's technology to try to optimize bone marrow transplants.
As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing novel companies with emerging data and collects best advice from experts on how start-ups should pitch to potential pharma partners.
Otsuka plans a slow, measured launch of Abilify MyCite, developed with Proteus Health. The product includes an ingested sensor that sends a signal to a wearable patch and an app that tracks ingestion, activity and mood to potentially improve management of psychiatric care.